350 related articles for article (PubMed ID: 25392322)
21. High-Resolution Expression Profiling of Peripheral Blood CD8
Roch L; Hecker M; Friess J; Angerer IC; Koczan D; Fitzner B; Schröder I; Flechtner K; Thiesen HJ; Meister S; Winkelmann A; Zettl UK
Mol Neurobiol; 2017 Sep; 54(7):5511-5525. PubMed ID: 27631876
[TBL] [Abstract][Full Text] [Related]
22. Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy.
Koczan D; Fitzner B; Zettl UK; Hecker M
Sci Data; 2018 Jul; 5():180145. PubMed ID: 30040082
[TBL] [Abstract][Full Text] [Related]
23. Applying T-cell receptor excision circles and immunoglobulin κ-deleting recombination excision circles to patients with primary immunodeficiency diseases.
Lee WI; Huang JL; Lin SJ; Yeh KW; Chen LC; Ou LS; Yao TC; Jaing TH; Shih YF; Tseng TY; Lin YL
Ann Med; 2014 Nov; 46(7):555-65. PubMed ID: 25109505
[TBL] [Abstract][Full Text] [Related]
24. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
25. FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.
Luessi F; Kraus S; Trinschek B; Lerch S; Ploen R; Paterka M; Roberg T; Poisa-Beiro L; Klotz L; Wiendl H; Bopp T; Jonuleit H; Jolivel V; Zipp F; Witsch E
Mult Scler; 2015 Dec; 21(14):1811-22. PubMed ID: 25732840
[TBL] [Abstract][Full Text] [Related]
26. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
[TBL] [Abstract][Full Text] [Related]
27. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.
Duszczyszyn DA; Beck JD; Antel J; Bar-Or A; Lapierre Y; Gadag V; Haegert DG
Clin Exp Immunol; 2006 Feb; 143(2):305-13. PubMed ID: 16412055
[TBL] [Abstract][Full Text] [Related]
28. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Immunol; 2018; 9():2669. PubMed ID: 30524432
[TBL] [Abstract][Full Text] [Related]
29. Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
Serpero LD; Filaci G; Parodi A; Battaglia F; Kalli F; Brogi D; Mancardi GL; Uccelli A; Fenoglio D
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1106-13. PubMed ID: 23649711
[TBL] [Abstract][Full Text] [Related]
30. Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Comi G; Gold R; Dahlke F; Sinha A; von Rosenstiel P; Tomic D; Kappos L
Mult Scler; 2015 May; 21(6):786-90. PubMed ID: 25257618
[TBL] [Abstract][Full Text] [Related]
31. Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
Schwichtenberg SC; Wisgalla A; Schroeder-Castagno M; Alvarez-González C; Schlickeiser S; Siebert N; Bellmann-Strobl J; Wernecke KD; Paul F; Dörr J; Infante-Duarte C
Neurotherapeutics; 2021 Jul; 18(3):1783-1797. PubMed ID: 34244929
[TBL] [Abstract][Full Text] [Related]
32. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
[TBL] [Abstract][Full Text] [Related]
33. Relationships of total leukocyte, neutrophil and lymphocyte levels with the menstrual cycle in patients receiving fingolimod treatment.
Ekmekyapar T; Ozcan C; Ciftci O
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):447-454. PubMed ID: 33506935
[TBL] [Abstract][Full Text] [Related]
34. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
[TBL] [Abstract][Full Text] [Related]
35. Prediction of disability progression in fingolimod-treated patients.
Lattanzi S; Danni M; Cerqua R; Taffi R; Provinciali L; Silvestrini M
J Neurol Sci; 2015 Nov; 358(1-2):432-4. PubMed ID: 26362335
[TBL] [Abstract][Full Text] [Related]
36. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
37. Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients.
Huber JE; Chang Y; Meinl I; Kümpfel T; Meinl E; Baumjohann D
J Immunol; 2020 Mar; 204(5):1101-1110. PubMed ID: 32034063
[TBL] [Abstract][Full Text] [Related]
38. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
Fenoglio C; De Riz M; Pietroboni AM; Calvi A; Serpente M; Cioffi SM; Arcaro M; Oldoni E; Scarpini E; Galimberti D
J Neuroimmunol; 2016 Oct; 299():81-83. PubMed ID: 27725128
[TBL] [Abstract][Full Text] [Related]
39. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
[TBL] [Abstract][Full Text] [Related]
40. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
Sato DK; Nakashima I; Bar-Or A; Misu T; Suzuki C; Nishiyama S; Kuroda H; Fujihara K; Aoki M
J Neuroimmunol; 2014 Mar; 268(1-2):95-8. PubMed ID: 24507619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
